Inoviv
Entrepreneur First '18London, GB · Founded 2018 · 20 employees on LinkedIn · 4 known investors
Find your way into Inoviv
814 people in our graph share verified history with the Inoviv team — schools, employers, funds. One of them is your warm intro.
Inoviv provides custom multiplexed LC-MS proteomics panels for biomarker discovery and analysis in drug discovery and development. The company delivers pre-validated mass spectrometry workflows with end-to-end support for research and clinical applications.
Founders & leadership
Inoviv was founded in 2018 by Ernestas Sirka.
Investors · 4
Company profile
researched Aug 2026Inoviv is a London-headquartered biomarker analysis company that provides multiplexed, fully quantitative liquid chromatography–mass spectrometry (LC-MS) proteomics services to pharmaceutical and biotechnology organisations. Its offering spans unbiased discovery proteomics screens, pre-validated off-the-shelf biomarker panels, and custom panels developed to a client's specification, covering proteins, post-translational modifications, lipids and metabolites. The company positions these services as an outsourced "in-house proteomics team", with support extending from biomarker selection through assay design and validation to bioinformatics analysis, interpretation and reporting.
Technically, Inoviv combines routine LC-MS assays (50+ calibrated biomarkers multiplexed, absolute quantification to ng/ml) with immunoprecipitation mass spectrometry (IP-MS) assays that use antibody-based enrichment to reach pg/ml sensitivity for low-abundance targets in a single 10-minute run, and data-independent acquisition (DIA) discovery workflows across thousands of samples. Stated assay performance includes coefficients of variation below 10% and a linear dynamic range of over six orders of magnitude, with full performance data (CV, LLOQ, linearity) supplied to clients. Sample types include plasma, serum, cerebrospinal fluid, urine, tissue (including FFPE) and cellular models or lysates. Therapeutic focus areas cited are neurology, fibrosis, oncology, cardiovascular disease and infectious diseases; branded panel lines referenced on the company website include FibroKey, NeuroKey-3 and the MasterKey catalogue.
Applications marketed by the company are mechanistic insight generation, patient stratification for clinical trial enrolment, treatment monitoring and companion diagnostic development. Analysis is performed in the company's UK laboratories, described as GCP/GLP certified, and US laboratories, described as CLIA certified and FDA inspected.
Founding story
Hoxton Ventures lists Michael Dove and Ernestas Sirka as founders and gives a founding year of 2017 (internal records state 2018).
Business model
Services/assay business: clients purchase pre-validated multiplexed biomarker panels or commission custom assay development and validation, with samples analysed in Inoviv's own laboratory network and results delivered as reports tying data to underlying biology. Turnaround is stated as within two months for pre-validated panels and three to four months for custom assays.
Traction
Investor funding from Hoxton Ventures (2021) and a subsequent round with Hoxton Ventures and Foresight Group intended to expand commercial activities and R&D capacity. The company operates laboratories in the UK and US and has expanded its panel pipeline from neurology and fibrosis toward oncology. No customer counts or revenue figures are disclosed in the sources.
Latest developments
The company website promotes the MasterKey v1.1 panel catalogue and on-demand webinars for the FibroKey and NeuroKey-3 panels, and lists a leadership team headed by CEO Dr Marie Labus with CFO Susan Robson, CMO Jane Meaney, CTO Martin Bachman, Scientific Director Dr Colin Brown, Associate Director of Bioanalysis Blandine Rougemont, and Chair Dr Sandy Primrose.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Presented by its investors as a targeted-proteomics platform for pharmaceutical biomarker test development; a London startup directory classifies the company at Series A stage within health tech and medical devices. Public sources do not provide market share or comparative benchmarking data.
Sources emphasise absolute quantification down to pg/ml for low-abundance biomarkers, multiplexing of 50+ calibrated biomarkers without cross-reactivity in a single run, CVs below 10% across thousands of samples, matrix-independent analysis, and regulatory-grade laboratory accreditation (GCP/GLP in the UK; CLIA-certified and FDA-inspected in the US).
Technology
Proprietary targeted mass spectrometry workflows spanning routine LC-MS multiplexed assays, hybrid immunoprecipitation-MS (IP-MS) assays that combine antibody enrichment with MS specificity, and DIA-based discovery proteomics. Reported breakthroughs include hybrid assays enabling multiplexing of previously immeasurable biomarkers and rapid standards development for quantitative workflows, supporting absolute quantification with 50+ calibrated analytes per sample.
Go-to-market
Direct consultative sales via website enquiry forms, expert consultations and scheduled panel selection, supported by content marketing including on-demand webinars (FibroKey, NeuroKey-3), a gated MasterKey panel catalogue and a newsletter. The company has appointed a Chief Marketing Officer tasked with scaling sales by rebuilding the commercial function.
Pharmaceutical and biotechnology companies conducting drug discovery, preclinical and clinical development, including teams needing clinical trial monitoring, patient stratification and companion diagnostic strategies.
Geography
Headquartered in London, UK, with a network of high-throughput laboratories: UK facilities described as GCP/GLP certified and US facilities described as CLIA certified and FDA inspected.
History
Hoxton Ventures records an initial investment in 2021 from its Hoxton III fund, with Rob Kniaz as the responsible partner. A later round added Foresight Group alongside Hoxton Ventures, announced with Michael Dove quoted as CEO. The company's website subsequently lists Dr Marie Labus as Chief Executive Officer, indicating a change in the CEO role.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with Inoviv for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsInoviv announced funding from Hoxton Ventures and Foresight Group, building on a previous Hoxton Ventures round, to expand commercial activities in clinical proteomics and clinical trial monitoring, extend R&D capacity, and accelerate its product pipeline from neurology and fibrosis into oncology. Amount not disclosed in the source.
Hoxton Ventures lists Inoviv as a portfolio company invested in during 2021 out of its Hoxton III fund, with partner Rob Kniaz.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Companies House · registry record
View on Companies House ↗- Registered name
- INOVIV LTD
- Company number
- 09868044
- Status
- Dissolved
- Company type
- Private limited company
- Incorporated
- 11 Nov 2015
- Dissolved
- 9 Apr 2019
- Registered office
- 1-2 Broadgate Cir, London, EC2M 2QS
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 30 Nov 2017
Current officers
- Michael James Dove — director, appointed 11 Nov 2015
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
▸Research sources · 8
primary sources listed
- Inovivinoviv.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Inoviv do?
- London-based Inoviv runs multiplexed, quantitative LC-MS proteomics biomarker panels for drug discovery and clinical development.
- Who founded Inoviv?
- Inoviv was founded by Ernestas Sirka in 2018.
- Who are Inoviv's investors?
- Inoviv's investors include Beast Ventures, Entrepreneur First, Hoxton Ventures, Foresight Group.
- Where is Inoviv headquartered?
- Inoviv is headquartered in London, GB.